Tilray: Haywood Slashes Price Target From $7.25 To $4.00

Tilray Brands (TSX: TLRY) is expected to report its fiscal fourth-quarter results on July 26th. The consensus revenue estimate is US$152.2 million, this estimate has slowly dropped over the last year as the original estimate was US$228 million. EBITDA is expected to come in at just US$11.28 million, this consensus estimate is also down from US$30 million. Lastly, the consensus estimate for net income is ($40) million.

Tilray currently has 19 analysts covering the stock with an average 12-month price target of US$6.84, which is an upside of 120%. Out of the 19 analysts, 2 have strong buy ratings, 2 have buy ratings, 13 analysts have hold ratings and the last 2 analysts have to sell ratings on the stock. The street high price target sits at US$23, or an upside of 630%.

In Haywood Capital Markets’ note on their fourth-quarter preview, they reiterate their hold rating but slash their 12-month price target from $7.25 to $4.00, saying that “with the recent Hifyre data and increasing competition within the Canadian adult-use landscape, we have lowered our revenue expectations for the cannabis segment.”

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

For the fiscal fourth quarter, Haywood lowered their estimates to be in line with the consensus estimates. They now expect revenues to come in at $153.3 million, which implies a 1% growth sequentially and only 8% on a year-over-year basis. They expect adjusted gross margins to come in at 26.9%, a 2.9% decrease year over year, while their adjusted EBITDA estimate is now $9.9 million, or a margin of 6.5% and flat on a quarter-over-quarter basis. They add that according to the most recent Hifyre data, Tilray has lost even more market share, falling almost 2% to 8.1% of the adult-use market.

On the strategic transaction with HEXO Corp (TSX: HEXO), Haywood says that the cost-saving of $80 million and the annual advisory fee of $18 million help offset the market share losses in Tilray’s Canadian adult-use segment.

Haywood adds though that they are optimistic for the company on its international opportunities, which mainly are its U.S investments. They remain cautious “on the overall Canadian landscape which drives a significant amount of its revenue growth opportunity.”

Lastly, Haywood has elected to lower their full-year 2023 estimates slightly and say that, “we will await a return to growth in the Canadian adult-use cannabis segment, strengthening of on-premise alcohol sales and results from the Whole Foods partnership prior to making any material near-term updates to our estimates.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A $2.2B Gold Project Is Outgrowing Its Plan | Michael Henrichsen – Gold X2 Mining

Pay for the Copper, Get the Gold Free | Rob McEwen – McEwen Inc

This Gold Discovery Was Already Huge. Now It’s Becoming a Monster. | Goliath Resources

Recommended

Rackla Metals Adds Two Northern Development Veterans to Board as Lentung Advances

Northmin Hits 12.85% Copper and 933 g/t Silver in Highest Grade Tynagh Assays Yet

Related News

Canaccord: Yamana Gold, Gold Fields Deal Is A “Surprise Combination”

On May 31, Gold Fields (NYSE: GFI) announced that they would be acquiring Yamana Gold...

Thursday, June 2, 2022, 03:56:27 PM

Equinox Gold Sees BMO Lower Price Target To $11.50

At the end of January, Equinox Gold Corp. (TSX: EQX) announced its 2022 production guidance....

Thursday, February 10, 2022, 06:04:00 PM

Alphabet: BMO Lowers Estimates Ahead Of Earnings Release Tomorrow

Alphabet (NASDAQ: GOOGL) announced that it will be reporting its quarterly financial results on October...

Monday, October 25, 2021, 10:06:00 AM

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and...

Wednesday, September 16, 2020, 04:15:00 PM

Eldorado Gold: BMO Reiterates $20 Price Target After Skouries Feasibility Study

On December 15th, Eldorado Gold (TSX: ELD) announced the results of the Skouries Project feasibility...

Monday, December 27, 2021, 11:04:00 AM